The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Biontech Cell&gene Therapies competitive analysis

Loading summary...

Latest patents of Biontech Cell&gene Therapies opposed by its competitors

Explore Biontech Cell&gene Therapies's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
EP3294333
Jul 9, 2025Claudin-18.2-Specific Immunoreceptors And T Cell Epitopes1
EP3294325
Jul 26, 2023Enhancing The Effect Of Car-Engineered T Cells By Means Of Nucleic Acid Vaccination1
EP3126381
Feb 16, 2022Claudin-6-Specific Immunoreceptors And T Cell Epitopes1

Latest PTAB cases involving Biontech Cell&gene Therapies

Discover the latest PTAB cases involving Biontech Cell&gene Therapies, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Biontech Cell&gene Therapies with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
BIONTECH CELL&GENE THERAPIES - 3 - -
DR H ULRICH DORRIES26 - - -
SCHIWECK WEINZIERL KOCH PATENTANWALTE PARTNERSCHAFT MBB22 - - -
WITHERS & ROGERS33 - - -